Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Prilenia Therapeutics

Evaluate

Thumbnail
May 25, 2023

Normal service resumes in amyotrophic lateral sclerosis

February 01, 2023

Novartis trims its pipeline

Discontinuations for branaplam, iptacopan and Piqray could increase pipeline scepticism, but more pruning is coming.

Article image
Vantage logo
August 09, 2022

Uniqure’s Huntington’s hopes take a hit

Article image
Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Article image
Vantage logo
March 31, 2022

Amylyx’s chances rest on a knife edge

Article image
Vantage logo
January 18, 2022

Roche and Ionis bring tominersen back from the dead

Article image
Vantage logo
January 05, 2022

Huntington’s hurt continues

Annexon becomes the latest group to provide a confusing update in the disease.

Article image
Vantage logo
December 17, 2021

Markets punish Uniqure for Huntington’s vagueness

Lack of clarity on safety and efficacy causes shareholders to decamp.

Article image
Vantage logo
December 08, 2021

Neurocrine provides some good news in Huntington’s

Ingrezza could have some advantages over approved therapies, but a more important Huntington’s readout nears.

Article image
Vantage logo
September 16, 2021

Biogen leads the amyotrophic lateral sclerosis hopefuls

Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.

Article image
Vantage logo
April 01, 2021

Prilenia hopes to buck the Huntington’s trend

Prilenia’s pridopidine is the last big late-stage hope in the disorder, but it already failed phase 2, and phase 3 under the name Huntexil.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up